Findings of two studies presented recently at the European Cancer Congress 2017 (ECCO 2017) demonstrates the effect of the PD-1 inhibitor, pembrolizumab, against a rare form of melanoma and bladder cancer.
The prevalence of benign prostate hypertrophy (BPH) increases with age and is more common in men aged 50 years and above. Dr Ronny Tan, consultant urologist and director of andrology at Tan Tock Seng Hospital, Singapore, speaks on how GPs can best manage this condition.
Uptake of the human papillomavirus (HPV) vaccine is low among vaccine-eligible men in the US, a recent study shows.
Extending the interval between doses of zoledronic acid does not increase skeletal events in individuals with bone metastases due to breast or prostate cancer, or multiple myeloma, according to a US study.